Profil
Joshua Weiyuan Wang is the founder of PathoVax LLC, where he holds the title of Chief Executive Officer & Director since 2014.
Dr. Wang is also the founder of Verimmune, Inc.
Postes actifs de Joshua Weiyuan Wang
| Sociétés | Poste | Début |
|---|---|---|
PathoVax LLC
 PathoVax LLC Miscellaneous Commercial ServicesCommercial Services PathoVax LLC engages in the provision of biotechnology services. It focuses on medical applications for its proprietary Papillomavirus Virus-like Particle platform. The company was founded by Joshua Wang, Weijie Poh, and Nicholas Calcaterra in 2014 and is headquartered in Baltimore, MD. | Fondateur | 01/01/2014 |
Verimmune, Inc.
 Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Directeur Général | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
PathoVax LLC
PathoVax LLC Miscellaneous Commercial ServicesCommercial Services PathoVax LLC engages in the provision of biotechnology services. It focuses on medical applications for its proprietary Papillomavirus Virus-like Particle platform. The company was founded by Joshua Wang, Weijie Poh, and Nicholas Calcaterra in 2014 and is headquartered in Baltimore, MD. | Commercial Services |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | Health Technology |